John C Byrd

6PUBLICATIONS
66CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 12, 2025
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Joshua F Zeidner, Tara L Lin, Rina Li Welkie

|Mar 29, 2024
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.

Adam S Kittai, David Bond, Ying Huang

|Jun 13, 2022
Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention.

Andrew Hantel, Jessica Kohlschmidt, Ann-Kathrin Eisfeld

|Nov 04, 2021
Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia.

Janek S Walker, Zachary A Hing, Steven Sher

|Jul 26, 2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.

John C Byrd, Peter Hillmen, Paolo Ghia

|Oct 27, 2020
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.

Amy Burd, Ross L Levine, Amy S Ruppert

Pageof 1

Frequent Collaborators

2 joint publications

Alice S Mims

2 joint publications

Brian J Druker

2 joint publications

Wendy Stock

2 joint publications

Jennifer A Woyach